---
marp: true
theme: default
paginate: true
backgroundColor: #ffffff
color: #1e3a5f
style: |
  section {
    font-family: 'Arial', sans-serif;
  }
  h1 {
    color: #1e3a5f;
    font-size: 2.2em;
  }
  h2 {
    color: #2d6a9f;
    font-size: 1.6em;
  }
  a {
    color: #48a9a6;
  }
  strong {
    color: #2d6a9f;
  }
  .columns {
    display: grid;
    grid-template-columns: 1fr 1fr;
    gap: 1em;
  }
  .highlight {
    background: #e8f4f8;
    padding: 0.5em 1em;
    border-left: 4px solid #48a9a6;
  }
  table {
    font-size: 0.85em;
  }
  th {
    background: #1e3a5f;
    color: white;
  }
---

<!-- _class: lead -->
<!-- _backgroundColor: #1e3a5f -->
<!-- _color: white -->

# Presentation Title
## Subtitle or Topic

**Your Name, MD**
Institution | Department

Date

---

# Disclosures

<!-- Modify as needed -->

- No relevant financial relationships to disclose
- *OR list your disclosures here*

---

# Learning Objectives

After this presentation, participants will be able to:

1. **Objective one** - describe key concept
2. **Objective two** - explain mechanism
3. **Objective three** - apply knowledge clinically

---

# Outline

1. Background & Epidemiology
2. Pathophysiology
3. Diagnosis
4. Management
5. Case Discussion
6. Take-Home Points

---

# Key Statistics

<div class="columns">
<div>

### Prevalence
- **6.7 million** Americans affected
- Rising with aging population
- 50% mortality at 5 years

</div>
<div>

### Cost
- **$30.7 billion** annually
- Leading cause of hospitalization
- Significant caregiver burden

</div>
</div>

---

# Pathophysiology

![bg right:40% fit](path/to/diagram.png)

<!-- Replace with actual image path -->

- Neurohormonal activation
- Cardiac remodeling
- Fluid retention
- Progressive dysfunction

---

# Diagnostic Algorithm

<!-- Use a flowchart here if available -->

```
Clinical Suspicion
       ↓
    BNP/NT-proBNP
       ↓
   Echocardiogram
       ↓
Classify HFrEF vs HFpEF
       ↓
   Risk Stratification
```

---

# Treatment Overview

| Class | Examples | Key Evidence |
|-------|----------|--------------|
| ACEi/ARB/ARNI | Enalapril, Sacubitril/Valsartan | PARADIGM-HF |
| Beta-blockers | Carvedilol, Metoprolol | MERIT-HF |
| MRA | Spironolactone, Eplerenone | RALES, EMPHASIS |
| SGLT2i | Dapagliflozin, Empagliflozin | DAPA-HF, EMPEROR |

---

# Landmark Trial Results

![bg right:50% fit](path/to/chart.png)

<!-- Replace with actual chart -->

**PARADIGM-HF**
- 20% reduction in mortality
- NNT = 21 over 27 months
- Changed standard of care

---

# Clinical Pearl

<div class="highlight">

**Start low, go slow, but GO!**

Uptitration of GDMT to target doses is associated with improved outcomes, but many patients remain on suboptimal doses.

</div>

---

# Case Presentation

**68-year-old male**

- Chief complaint: Progressive dyspnea
- PMH: HTN, T2DM, prior MI
- Exam: JVD, S3, peripheral edema
- Labs: BNP 1,200 pg/mL
- Echo: LVEF 30%, moderate MR

**What is your approach?**

---

# Case Discussion

<div class="columns">
<div>

### Initial Management
- IV diuretics
- Optimize volume status
- Start GDMT

</div>
<div>

### Long-term Plan
- Titrate medications
- Cardiac rehabilitation
- Device evaluation
- Follow-up in 2 weeks

</div>
</div>

---

# Take-Home Points

1. ✅ **Early diagnosis** improves outcomes
2. ✅ **Quadruple therapy** is now standard
3. ✅ **Titrate to target doses** when tolerated
4. ✅ **Consider devices** in appropriate patients
5. ✅ **Multidisciplinary care** reduces readmissions

---

# Questions?

<br>

**Contact Information**
your.email@institution.edu

<br>

**Slides Available**
[Link to slides or QR code]

---

# References

1. Author et al. *Journal*. Year;Volume:Pages.
2. Author et al. *Journal*. Year;Volume:Pages.
3. Author et al. *Journal*. Year;Volume:Pages.

<br>

*Full reference list available upon request*

---

<!-- _class: lead -->
<!-- _backgroundColor: #1e3a5f -->
<!-- _color: white -->

# Thank You

Questions and Discussion
